Anthony Johnson, President and Chief Executive Officer of Domain Therapeutics, and Sean A. MacDonald, Chief Business Officer to engage in key industry events in Q2 2024 Domain’s leadership will provide a corporate overview including advancements of key drug candidates in immuno-oncology: DT-9081 currently in Phase I ascending dose, as well as DT-7012 and DT-9045 in […]
